BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Lynk Pharmaceuticals Announces First Participants in Phase I Trial of LNK01004

This study is to evaluate the safety, tolerability, and pharmacokinetics of the LNK01004 ointment in healthy adults and patients with mild to moderate plaq...

July 29, 2022 | News

Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy

Independent lab results demonstrate that the combination therapy retains neutralizing activity against currently dominant COVID-19 strains, as previously d...

July 27, 2022 | News

Brii Bio Announces Strategic Partnership with China Resources Pharmaceutical Commercial Group

The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China The ...

July 20, 2022 | News

WuXi STA Opens a New Large Scale Continuous Manufacturing Plant

WuXi STA, a subsidiary of WuXi AppTec, announced that it has opened a new continuous manufacturing (flow chemistry) plant at its Changzhou campus in ...

July 20, 2022 | News

China CDE Grants Breakthrough Therapy Designation (BTD) to Neurophth's NR082 in LHON

NR082 (rAAV2-ND4), a recombinant adeno-associated viral vector, serotype 2, containing human ND4 codon-optimized gene under the control of the cy...

July 18, 2022 | News

Pulnovo Medical Concludes Successfully First Pre-Sub Meeting with FDA for PADN Global Clinical Trial

Dr. Shaoliang Chen, Chair of Pulnovo Medical's Scientific Advisory Board and pioneer of the PADN technology, attended the meeting and presented the co...

July 18, 2022 | News

Merck Launches its Uptune Program in Asia for Collaborating with Startups

Application period for the Merck Uptune program starts today Topics vary from AI-enabled health and cell and gene therapy tools to innovative technologi...

July 15, 2022 | News

Triastek & Lilly to explore the application of 3D printing technology in oral delivery of drugs

According to the agreement, the project will focus on the targeted release of drugs in the intestine. Triastek will focus on two aspects: Firstly, conduct ...

July 14, 2022 | News

Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China

Brii Bio progressed the combination therapy from discovery to global Phase 3 data readout and first regulatory approval by the China NMPA in les...

July 07, 2022 | News

WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility

WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at its Chan...

July 07, 2022 | News

Enosi Therapeutics Partners with Danuo Science Group to Accelerate Multiple Therapeutic Programs

Enosi Therapeutics, a Delaware Corporation, focused on providing industry-leading therapeutics for cancer and autoimmune diseases, has announced a partners...

July 06, 2022 | News

WuXi Biologics Extends Capabilities to Include Development and cGMP Manufacturing for Microbial-Derived Products

WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG14 fac...

July 05, 2022 | News

WuXi STA Opens A High-Potency API Plant

The new plant adopts advanced isolation technologies with the capability to handle potent compounds with Occupational Exposure Limit (OEL) as low as 10 ng/...

June 29, 2022 | News

Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies

Palleon Pharmaceuticals Inc., a company pioneering the field of glyco-immunology to treat cancer and inflammatory diseases, today announced a str...

June 29, 2022 | News

Stay Connected